AI Article Synopsis
- - Targeted therapies for non-small cell lung cancer (NSCLC) have greatly improved patient survival rates and have fewer side effects.
- - Genetic testing for specific mutations, like EGFR and ALK/ROS1, is crucial for patients with advanced NSCLC, especially those with adenocarcinoma.
- - The review highlights new potential drug targets in NSCLC, including mutations and rearrangements in MET, RET, BRAF, KRAS, NTRK, and HER2.
Article Abstract
In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176852 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.632256 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!